The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
Intra-Cellular Therapies’ pipeline is focused on the following platforms: lumateperone, ITI-1284-ODT-SL, phosphodiesterase 1 (PDE1) inhibitors, ITI-333 and ITI-1500 series.
ITI-1284 is a deuterated form of lumateperone, a new chemical entity formulated as an oral disintegrating tablet for sublingual administration.
ITI-333 is a novel compound that acts as a partial agonist at mu-opioid (MOP) receptors and as an antagonist at the serotonin 5-HT2A receptors.
ITI-1500 series is our portfolio of Non-Hallucinogenic Psychedellics. ITI-1549 is our lead product candidate in this program.